Vifor Pharma appoints Hervé Gisserot as new Chief Commercial Officer and member of the Executive Committee
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma Group today announced the appointment of Hervé Gisserot as Chief Commercial Officer and member of the Vifor Pharma Executive Committee as of 17 January 2022.
Hervé Gisserot, a French citizen, is an experienced industry executive and has a proven track record of building and leading organizations across the U.S., Europe and Asia Pacific with extensive launch and market access experiences. He joins from GlaxoSmithKline where he served in multiple Senior Vice President roles in the last 13 years. He is a graduate of the Institute of Political Science Paris (IEP), and has completed the General Management program at INSEAD.
With this new appointment, the President US, the Regional Commercial Heads, the Rare Disease BU, the central commercial, marketing and pricing teams, will report to the Chief Commercial Officer. This is to lead the organization ahead of expected approvals and subsequent launches of four pipeline products in the next 18 months, and to maximize opportunities of our iron portfolio.
Abbas Hussain, Chief Executive Officer of Vifor Pharma Group, commented: “I am delighted that Hervé joins Vifor Pharma. He brings a wealth of commercial experience from leading pharmaceutical companies at an international level, delivering profitable growth across multiple therapeutic areas and markets. His professional background makes him ideally suited to lead the commercial organization and to put a strong focus on execution as we accelerate growth to become a multi-brand organization focused on in-licensing, partnering and commercializing products worldwide.”
A picture of Hervé Gisserot is available for download at viforpharma.com/media/media-library
About Vifor Pharma Group
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).
For more information, please visit viforpharma.com .
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
DEWA-PJSC13.8.2022 10:01:09 CEST | Press release
Dubai Electricity and Water Authority PJSC announces AED 12.08 billion revenue and 3.30 billion net profit in the first half of 2022
TX-MARY-KAY-INC.12.8.2022 18:35:07 CEST | Press release
Mary Kay Inc. Continues Its Support of Women’s Empowerment at the International Women’s Forum Cornerstone Conference in Chile
IPSEN12.8.2022 17:37:08 CEST | Press release
Ipsen Completes Acquisition of Epizyme Expanding Its Portfolio in Oncology
Q4-INC.12.8.2022 13:02:12 CEST | Press release
Q4 Inc. Announces Second Quarter 2022 Results
BUDWEISER12.8.2022 13:02:12 CEST | Press release
Budweiser Celebrates 100 Days to The FIFA World Cup™ by Partnering with Messi, Neymar Jr. and Sterling to Drop Hundreds of Prizes For Fans Around the World
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom